<DOC>
	<DOCNO>NCT02802813</DOCNO>
	<brief_summary>This study aim determine whether 14 day course 0.5 mg/kg/day primaquine eliminate subclinical P. vivax infection detect high volume ultra-sensitive PCR ( uPCR ) .</brief_summary>
	<brief_title>P.Vivax Treatment Trial</brief_title>
	<detailed_description>This randomize , double blind trial G6PD normal participant subclinical P. vivax infection Laos . Participants subclinical P. vivax infection meeting enrolment criterion randomly assign one two treatment arm : - Intervention : Dihydroartemisinin-piperaquine ( DP ) therapy 3 day dose plus 14 day supervise primaquine ( 7mg/kg total dose ) administer per day ( 0.5 mg/kg/day ) . - Control arm : Dihydroartemisinin-piperaquine ( DP ) 3 day dose therapy plus 14 day identical primaquine placebo . Participants find G6PD deficient ( G6PDd ) treat primaquine 0.75mg/kg/week 8 week accord WHO recommendation . Primaquine placebo administer food ( biscuit ) , show reduce gastrointestinal side effect . All dos study drug supervise . If participant visit study centre , fail attend 14 day supervise therapy , team member visit home , school work ensure complete dosing .</detailed_description>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>Participants subclinical mono mixed P. vivax infection ( uPCR ) enrol . Able participate decide investigator , willing comply study requirement followup . A participant ( parent/guardian child age consent ) willing able give write informed consent participate trial . Currently pregnant breastfeeding ( female childbearing age ) . Inability tolerate oral treatment . Previous episode haemolysis severe haemoglobinuria follow primaquine . Known hypersensitivity allergy study drug . Blood transfusion last 90 day , since mask G6PD deficiency . An acute malaria episode require treatment . A febrile condition due disease malaria ( e.g . measles , acute low respiratory tract infection , severe diarrhoea dehydration ) . Anaemia ( Haemoglobin ( Hb ) &lt; 9 g/dL Presence condition judgment investigator would place participant undue risk interfere result study ( e.g . serious underlying cardiac , renal hepatic disease ; severe malnutrition ; HIV/AIDS ; severe febrile condition malaria ) ; coadministration medication know cause haemolysis could interfere assessment antimalarial regimen . Currently take medication know interfere significantly pharmacokinetics primaquine schizontocidal study drug</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Double-blinded control trial</keyword>
	<keyword>Primaquine</keyword>
</DOC>